SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle

SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions, according to a person familiar with the situation and employee posts on social media.

It is the latest in a series of retrenchments by high-profile gene-editing companies. A spokesperson for SalioGen declined to comment.

Launched in 2021, SalioGen was among a group of new startups developing technology for inserting full-length genes into patients — a feat that can’t readily be accomplished with older approaches based on the gene-editing technology CRISPR.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

For clinician-administered drugs, researchers find no association between price increases and OOP cost increases

It seems obvious to assume that patient out-of-pocket costs would increase as drug companies raise the prices of their drugs. But a new study published

January 23, 2024

Opinion | ‘The Data Do Not Even Exist’: What We Heard This Week

“Heck — the data do not even exist.” — Becky Smullin Dawson, PhD, MPH, of Allegheny College in Meadville, Pennsylvania, on a controversial BMJ Public

June 24, 2024

McConnell Speculation; Army Doc Charged; Ice Cream Recall Over Listeria Concerns

Note that some links may require registration or subscription. Also note that Morning Break will be taking a break on Monday in observance of Labor

September 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.